Evidence map›Paper›PMID 41115627›Full record

ReviewProgress in retinal and eye research2026

Clinical histopathology and pathogenesis of macular telangiectasia type 2.

Dimitrios P Ntentakis, Anastasia Maria Ntentaki, Eleni Delavogia, Gustavo Sakuno, Victor S M C Corrêa, Nikolaos E Efstathiou, Mary E Aronow, Emily Y Chew, Joan W Miller, Demetrios G Vavvas

Abstract readReview
In one paragraph

Review in Progress in retinal and eye research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Macular telangiectasia type 2: An update.The Journal of international medical research · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dimitrios P NtentakisRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, 243 Charles St., 02114, Boston, MA, United States of America.
Anastasia Maria NtentakiRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, 243 Charles St., 02114, Boston, MA, United States of America.
Eleni DelavogiaDepartment of Pediatrics, Mass General for Children, Harvard Medical School, 55 Fruit St., 02114, Boston, MA, United States of America.
Gustavo SakunoRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, 243 Charles St., 02114, Boston, MA, United States of America.
Victor S M C CorrêaRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, 243 Charles St., 02114, Boston, MA, United States of America.
Nikolaos E EfstathiouRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, 243 Charles St., 02114, Boston, MA, United States of America.
Mary E AronowEarly Clinical Development in Ophthalmology, Metabolism, Neuroscience and Immunology (ECD-OMNI), Genentech, a Member of the Roche Group, 1 DNA Way, 94080, South San Francisco, CA, United States of America.
Emily Y ChewDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, 31 Center Dr. MSC 2510, 20892-2510, Bethesda, MD, United States of America.
Joan W MillerRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, 243 Charles St., 02114, Boston, MA, United States of America.
Demetrios G VavvasRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, 243 Charles St., 02114, Boston, MA, United States of America. Electronic address: Demetrios_Vavvas@MEEI.HARVARD.EDU.

Funding

Necroptosis, neuroprotection and axonal regeneration in retina ganglion cell injuryR01EY025362 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI VAVVAS, DEMETRIOS · 2015 to 2018
$1.5M
Necroptosis and Neuroprotection in AMDR21EY023079 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI VAVVAS, DEMETRIOS · 2013 to 2014
$404k
NEI NIH HHS R01 EY025362NEI NIH HHS R21 EY023079
6 · The paper itself

Abstract

Macular telangiectasia type 2 (MacTel) is a rare neurodegenerative retinal disease defined by a unique combination of reduced macular pigment, a characteristic angiographic pattern, and a localized clinical presentation. The condition typically affects the temporal perifovea and leads to progressive visual impairment. No definitive treatment exists. Current management is limited to intravitreal anti-vascular endothelial growth factor (VEGF) injections for end-stage neovascular complications and the recently approved Encelto implant (Neurotech Pharmaceuticals, Inc.), which delivers ciliary neurotrophic factor (CNTF) for neuroprotection. To clarify the still enigmatic pathophysiology of MacTel, we conducted a comprehensive review of all human histopathology reports published in English through December 31, 2024. Findings were systematically evaluated with respect to tissue processing techniques, postmortem fixation times, disease stage at last recorded ophthalmologic evaluation, diagnostic certainty, inclusion of control specimens, and the anatomic origin of analyzed retinal sections. This approach aimed to identify histopathologic features most likely to represent core disease mechanisms. Each of the features identified as most likely to be pathophysiologically relevant was independently assessed for clinical and histopathologic specificity. These features were then further interpreted in the context of genetic, metabolic, and anatomic associations reported in the literature. Donor demographics, coexisting ocular conditions, and systemic comorbidities were also reviewed to support the development of an integrative hypothesis for MacTel pathogenesis. Drawing on this synthesis, we propose a histopathology-informed model of disease pathophysiology and outline a provisional timeline for the contribution of key factors to clinical expression. We also review current neuroprotective strategies and provide targeted recommendations for future therapeutic development and histopathologic research. The conceptual framework developed in this work -grounded in rigorous analysis of the most consistent and methodologically validated histopathologic findings, and interpretation of their mechanistic context- may serve as a model for deciphering rare retinal diseases and for generating focused, hypothesis-driven questions to guide future investigation.

Indexed as

Retinal TelangiectasisFluorescein AngiographyHumansTomography, Optical CoherenceAcquired hypoperfusionDysfunctional serine synthesisGlucose homeostasisHuman histopathologyMacular telangiectasiaMüller cell degenerationPhotoreceptor degenerationSerine homeostasisTemporal perifoveaVascular comorbidities

Identifiers

PMID41115627
PMCPMC12747724

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.